<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; clause</title>
	<atom:link href="http://www.tapanray.in/tag/clause/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Discretionary ‘Non-Compete Clause’ in Pharma FDI: An Intriguing Decision</title>
		<link>http://www.tapanray.in/discretionary-non-compete-clause-in-pharma-fdi-an-intriguing-decision/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=discretionary-non-compete-clause-in-pharma-fdi-an-intriguing-decision</link>
		<comments>http://www.tapanray.in/discretionary-non-compete-clause-in-pharma-fdi-an-intriguing-decision/#comments</comments>
		<pubDate>Fri, 10 Jan 2014 07:05:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[clause]]></category>
		<category><![CDATA[compete]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[discretionary]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[Note]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Press]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TWN]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4848</guid>
		<description><![CDATA[As I had commented before, the MNC investors, while acquiring controlling stake in the Indian pharmaceutical companies, henceforth, would not be generally allowed to include any ‘non-compete clause’ in their agreement with the Indian promoters. However, this clause may be &#8230; <a href="http://www.tapanray.in/discretionary-non-compete-clause-in-pharma-fdi-an-intriguing-decision/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/discretionary-non-compete-clause-in-pharma-fdi-an-intriguing-decision/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
